Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial

被引：0

作者：

Humrich, Jens ^{[1
]}

von Spee-Mayer, Caroline ^{[2
]}

Siegert, Elise ^{[3
]}

Rose, Angelika ^{[2
]}

Bertolo, Martina ^{[4
]}

Enghard, Philipp ^{[5
]}

Hiepe, Falk ^{[6
]}

Alexander, Tobias ^{[3
]}

Feist, Eugen ^{[6
]}

Radbruch, Andreas ^{[7
]}

Burmester, Gerd R. ^{[6
]}

Riemekasten, Gabriela ^{[8
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Rheumatol, Campus Lubeck, Lubeck, Germany

[2] Charite, Rheumatol & Clin Immunol, Berlin, Germany

[3] Charite Univ Med Berlin, Rheumatol & Clin Immunol, Berlin, Germany

[4] Charite Univ Med Berlin, Dept Rheumatol, Berlin, Germany

[5] Charite Univ Med Berlin, Dept Nephrol, Berlin, Germany

[6] Charite, Berlin, Germany

[7] Deutsch Rheumaforschungszentrum, Berlin, Germany

[8] Univ Klinikum Schleswig Holstein, Dept Rheumatol, Lubeck, Germany

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

13L

引用

页数：3

共 50 条

[21] Low-dose IL-2 therapy — a complex scenario that remains to be further explored
Jens Y. Humrich
Gabriela Riemekasten
[J]. Nature Reviews Rheumatology, 2017, 13 : 386 - 386
[22] Low-dose IL-2 therapy - a complex scenario that remains to be further explored
Humrich, Jens Y.
Riemekasten, Gabriela
[J]. NATURE REVIEWS RHEUMATOLOGY, 2017, 13 (06) : 386 - 386
[23] Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer.
Pantuck A.J.
Belldegrun A.S.
[J]. Current Urology Reports, 2001, 2 (1) : 33 - 9
[24] Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE
Haotian Zhou
Xiaozhen Zhao
Ruijun Zhang
Miao Miao
Wenwen Pei
Zijun Li
Yimin Li
Jing He
Zhanguo Li
Xiaolin Sun
[J]. Signal Transduction and Targeted Therapy, 8
[25] Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE
Zhou, Haotian
Zhao, Xiaozhen
Zhang, Ruijun
Miao, Miao
Pei, Wenwen
Li, Zijun
Li, Yimin
He, Jing
Li, Zhanguo
Sun, Xiaolin
[J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
[26] Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial
Wang, Jia
Zhang, Sheng-Xiao
Chang, Jia-Song
Cheng, Ting
Jiang, Xiao-Jing
Su, Qin-Yi
Zhang, Jia-Qi
Luo, Jing
Li, Xiao-Feng
[J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
[27] Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
Humrich, Jens Y.
von Spee-Mayer, Caroline
Siegert, Elise
Alexander, Tobias
Hiepe, Falk
Radbruch, Andreas
Burmester, Gerd-Ruediger
Riemekasten, Gabriela
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (04) : 791 - U196
[28] Low-dose IL-2 therapy expands human regulatory T cell populations
[J]. Nature Reviews Immunology, 2012, 12 (1) : 6 - 6
[29] RESPONSE OF THERAPY-RELATED REFRACTORY-ANEMIA WITH EXCESS BLASTS (RAEB) TO LOW-DOSE INTERLEUKIN-2 (IL-2)
TOZE, C
BARNETT, MJ
KLINGEMANN, HG
[J]. EXPERIMENTAL HEMATOLOGY, 1992, 20 (06) : 712 - 712
[30] Rituximab Therapy for Refractory Scleritis Results of a Phase I/II Dose-Ranging, Randomized, Clinical Trial
Suhler, Eric B.
Lim, Lyndell L.
Beardsley, Robert M.
Giles, Tracy R.
Pasadhika, Sirichai
Lee, Shelly T.
de Saint Sardos, Alexandre
Butler, Nicholas J.
Smith, Justine R.
Rosenbaum, James T.
[J]. OPHTHALMOLOGY, 2014, 121 (10) : 1885 - 1891

← 1 2 3 4 5 →